NCT06111872View on ClinicalTrials.gov

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

February 27, 2024

Study Completion Date

October 25, 2024

Conditions
CholangitisPancreatic CancerCholedocholithiasisCholedochal Cyst
Interventions
DRUG

Ketamine

Administration described in arm/ group description

DRUG

Midazolam

Administration described in arm/ group description

DRUG

Pethidin

Administration described in arm/ group description

Trial Locations (1)

56000

Hospital Canselor Tuanku Muhriz UKM, Cheras

All Listed Sponsors
lead

National University of Malaysia

OTHER